Literature DB >> 16686766

Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease.

R C Verdonk1, G Dijkstra, E B Haagsma, V K Shostrom, A P Van den Berg, J H Kleibeuker, A N Langnas, D L Sudan.   

Abstract

Inflammatory bowel disease (IBD) is associated with primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) and can recur or develop de novo after orthotopic liver transplantation (OLT). The aim of this study was to investigate the incidence and severity of IBD after liver transplantation and to perform a multivariate analysis for possible risk factors. In this retrospective study, 91 patients transplanted for PSC or AIH, without prior colectomy, were included. Sixty patients were transplanted for PSC, 31 for AIH. IBD activity before and after OLT and other possible risk factors were analysed in a multivariate model. Forty-nine patients (54%) had IBD before OLT. Forty patients (44%) had active IBD after transplantation: recurrence in 32 and de novo in 8. Cumulative risk for IBD after OLT was 15, 39 and 54% after 1, 5 and 10 years, respectively. In 59% of patients with IBD prior to OLT the disease was more active after transplantation. Risk factors for recurrent disease were: symptoms at time of OLT, short interval of IBD before OLT and use of tacrolimus. 5-aminosalicylates were protective. A cytomegalovirus positive donor/negative recipient combination increased the risk for de novo IBD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686766     DOI: 10.1111/j.1600-6143.2006.01333.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  34 in total

1.  Cytomegalovirus infection increases the risk for inflammatory bowel disease.

Authors:  Robert C Verdonk; Elizabeth B Haagsma; Jan H Kleibeuker; Gerard Dijkstra; Debra L Sudan
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

2.  Answers to multiple choice questions.

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-12

Review 3.  Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients.

Authors:  Bettina M Buchholz; Panagis M Lykoudis; Reena Ravikumar; Joerg M Pollok; Giuseppe K Fusai
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 4.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

5.  A Review of Inflammatory Bowel Disease in the Setting of Liver Transplantation.

Authors:  Veena Nannegari; Saenz Roque; David T Rubin; Rodrigo Quera
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-10

6.  Inflammatory bowel disease after allogeneic stem cell transplantation.

Authors:  I Boussen; H Sokol; S Aractingi; O Georges; N Hoyeau-Idrissi; J P Hugot; M Mohty; M T Rubio
Journal:  Bone Marrow Transplant       Date:  2015-06-08       Impact factor: 5.483

Review 7.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 8.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

Review 9.  Management of ulcerative colitis pre- and post-liver transplant for primary sclerosing cholangitis: two case reports and review of literature.

Authors:  Kiranpreet Khosa; Kofi Clarke
Journal:  Int J Colorectal Dis       Date:  2014-07-04       Impact factor: 2.571

10.  Risk of Colorectal Cancer After Solid Organ Transplantation in the United States.

Authors:  M Safaeian; H A Robbins; S I Berndt; C F Lynch; J F Fraumeni; E A Engels
Journal:  Am J Transplant       Date:  2016-01-05       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.